


## Supplementary Information

Comprehensive T cell repertoire characterization of non-small cell lung cancer




**Supplementary Figure 1. T cell density, richness, and clonality are intercorrelated.**

**A)** Estimated T cell density as measured as the proportion of T cells in each tumor sample.


**B)** T cell richness as quantified by the unique TCR rearrangements in each tumor sample.

**C)** T cell clonality in each tumor sample. Correlation between **D)** T cell density and


richness, **E)** T cell density and clonality, and **F)** T cell richness and clonality.



**Supplementary Figure 2. Regulatory and cytotoxic T cells are major components of the tumor microenvironment in NSCLC. A)** Heatmap depicting the correlation between the density of evaluated T cell markers. **B)** Number of CD4 and CD8 T cells per mm<sup>2</sup> in each tumor sample. **C)** Ratio of CD4:CD8 in each tumor sample. **D)** Correlation between CD4 and FoxP3 density. **E)** Correlation between CD8 and GzmB density. Bars represent median and quartiles.




**Supplementary Figure 3. T cell density and richness are correlated with both CD4 and CD8 density.** Correlation between T cell density by TCR sequencing and **A)** CD3, **B)** CD4, and **C)** CD8 density by IHC. Correlation between T cell richness by TCR sequencing and **D)** CD3, **E)** CD4, and **F)** CD8 density by IHC.




**Supplementary Figure 4. T cell clonality is highest in tumors with a low CD4 density.**


**A)** T cell density, **B)** richness and **C)** clonality in tumors with higher CD3 density at the periphery or center of the tumor. **D)** T cell density, **E)** richness and **F)** clonality in tumors with higher CD4 density at the periphery or center of the tumor. **G)** T cell density, **H)** richness and **I)** clonality in tumors with higher CD8 density at the periphery or center of the tumor. Bars represent median and quartiles.



**Supplementary Figure 5. An increased tumor mutational burden is associated with improved quality of the T cell response. A)** Tumor mutational burden (non-synonymous exonic mutations - NSEM) in non-small cell lung cancer tumors by whole exome sequencing. Correlation between tumor mutational burden and **B)** CD3 density, **C)** CD4 density, **D)** CD8 density, **E)** CD4:CD8 ratio, **F)** GzmB density by IHC and **G)** GzmB expression by GEP.




**Supplementary Figure 6. T cell clonality is not associated with loss of HLA heterozygosity. A) T cell density, B) richness and C) clonality in tumors exhibiting loss (true) or no loss (false) in HLA heterozygosity (LOH). Bars represent median and quartiles.**




**Supplementary Figure 7. The T cell repertoire is not associated with tumor mutational burden in tumors with EGFR mutations.** Comparison of **A)** T cell density, **B)** richness and **C)** clonality in *EGFR* mutant tumors with a high (white) or low (red) TMB. Correlation between TMB and **D)** T cell density, **E)** richness and **F)** clonality in *EGFR* mutant tumors. Bars represent median and quartiles.







**Supplementary Figure 8. Increased T cell clonality is observed in poorly-differentiated NSCLC tumors. A) T cell density, B) richness and C) clonality in well, moderately and poorly-differentiated NSCLC tumors. Bars represent median and quartiles.**




**Supplementary Figure 9. The T cell repertoire is associated with clinicopathologic attributes. A)** T cell clonality in patients with adenocarcinoma (ADCA) and squamous cell carcinoma (SCCA). **B)** T cell density and **C)** richness in current, former, and never smokers. Bars represent median and quartiles.




**Supplementary Figure 10. Diversity and clonality of the T cell repertoire are correlated across the peripheral blood, tumor-adjacent uninvolved lung and tumor. Correlation between **A)** T cell density, **B)** T cell richness and **C)** T cell clonality across the peripheral blood, tumor-adjacent uninvolved lung, and tumor. p-values are listed in each cell.**




**Supplementary Figure 11. Substantial T cell repertoire homology between the tumor-adjacent uninvolved lung and tumor. A)** Morisita Overlap Index in the T cell repertoire between PBMC, tumor-adjacent uninvolved lung, and tumor. **B)** Morisita Overlap Index in the T cell repertoire when comparing the tumor-adjacent uninvolved lung to tumors, lung-enriched (E) T cell repertoire between the tumor-adjacent uninvolved lung and tumor, and different regions of the same tumor (ITH). Bars represent median and quartiles.



**Supplementary Figure 12. A substantial number of CDR3 $\beta$  TCR sequences are shared across patients with NSCLC.** Number of CDR3 $\beta$  TCR sequences shared across **A)** all tissues in all patients, **B)** only in blood samples, **C)** only in uninvolved adjacent lungs, or **D)** only in NSCLC tumors.



**Supplementary Figure 13. Mutations in the tumor and uninvolved lung impact the reactivity of tumor-infiltrating lymphocytes.** Correlation between T cell clonality in the tumor and the proportion of mutations **A)** unique to the tumor, **B)** unique to the tumor-adjacent uninvolved lung, or **C)** shared between the tumor and tumor-adjacent uninvolved lung.



**Supplementary Figure 14. A more tumor-focused lung T cell repertoire is associated with improved outcome. A) Proportion of mutations and B) T cells shared between the tumor-adjacent uninvolved lung and tumor in patients who relapsed and those who did not. Bars represent median and quartiles.**

**Supplementary Table 1. Samples and analyses included in our study.**

Assay	Tissue		
	Blood	Uninvolved Lung	Tumor
Whole exome sequencing	96	222	222
RNA microarray	---	---	141
Immunohistochemistry	---	---	146
TCR sequencing	120	216	236
GLIPH	---	168	168